Shares of Orexigen (OREX +16.7%
) are soaring after Credit Suisse initiates coverage
with an Outperform, saying it likes the prospects of a trial that will look at the cardiovascular impact of Contrave. Leerink Swann also recommends investors buy it aggressively. Meanwhile, it starts Arena Pharmaceutical (ARNA -4.6%
) with an Underperform
, saying Belviq may not generate enough revenue to justify the stock's current valuation.